Amgen

Amgen names executive VP

Wednesday, October 19, 2011 01:50 PM

Amgen has named Anthony (Tony) Hooper, executive vice president, global commercial operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer.

More... »

Amgen names Bradway to board of directors

Friday, October 14, 2011 11:03 AM

Amgen has named Robert A. Bradway to its board of directors. Bradway is Amgen's president and chief operating officer. The addition of Bradway brings the number of Amgen board members to 13.

More... »

Amgen to create hundreds of jobs in Dublin

Tuesday, August 23, 2011 10:26 AM

US drug firm Amgen plans to create 100 high-tech jobs at a new factory in Dublin just months after it saved 280 jobs by taking over a Pfizer plant that was earmarked for closure, according to The Post.

More... »

Affymax names VP, clinical development

Wednesday, August 3, 2011 12:29 PM

Affymax has named Krishna Polu, M.D. vice president, clinical development. Dr. Polu, a nephrologist, joined Affymax in 2009 as executive director, clinical development.

More... »

Micromet collaborates with Amgen

Tuesday, July 12, 2011 10:03 AM

Micromet has entered into a collaboration agreement with Amgen for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.

More... »

Amgen, UCB experiment with NASA

Wednesday, July 6, 2011 01:17 PM

Amgen and UCB are collaborating with the National Aeronautics and Space Administration (NASA) to conduct a pre-clinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis on the final NASA shuttle mission, Space Shuttle Flight STS-135.

More... »

Amgen to cut 150 jobs in Colorado

Friday, June 3, 2011 01:59 PM

Amgen has notified about 150 of its Longmont-Boulder, Colo., employees that their jobs will be eliminated Aug. 1, according to The Denver Post.

More... »

Amgen's Xgeva delays prostate cancer metastasis

Wednesday, May 18, 2011 12:22 PM

Results from a phase III trial of Amgen's Xgeva have demonstrated that the drug is able to delay the progression of prostate cancer into the bone, which could increase its market potential, according to Pharma Times.

More... »

Amgen and UCB report positive results for osteoporosis study

Tuesday, April 26, 2011 01:32 PM

California-based Amgen and Belgium-based UCB reported positive results from their phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). The 12-month phase 2 study is a multi-center, international, randomized, placebo-controlled and parallel-group study.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »